Nicotinamide adenine dinucleotide (NAD+) is a research hotspot of scientists at home and abroad. Most scientists believe that the level of NAD+ is closely related to age-related chronic diseases, such as cancer, obesity, hypertension and diabetes.
Keratinocyte carcinoma (KC) is the most common malignant tumor in fair-skinned people, including basal cell carcinoma (BCC) and squamous cell carcinoma (cSCC). Recently, American scientists published a discussion article in J DRUGS DERMATOL on supplementing NAD precursors NMN and NR to reduce the risk of keratinocyte cancer.
The author thinks that nicotinamide (NAM), as the precursor of NAD+, has been proved by Choy B and other scientists to reduce the incidence of keratinocyte cancer. However, nicotinamide mononucleotide (NMN) and nicotinamide nucleoside (NR), which are also precursors of NAD+ synthesis, may be a more effective supplement to reduce the incidence of keratinocyte cancer.
Oral administration of NMN and NR can effectively increase the level of NAD+
In 2018, Sinclair DA and other scientists proved that compared with NAM, taking NMN and NR orally to treat humans and mice increased the level of NAD+ in blood and liver, respectively. As a result, NMN and NR synthesized NAD+ more efficiently.
NMN and NR are safe and better tolerated
NMN and NR supplements have been widely used in humans and animals, and no toxicity or serious side effects have been reported so far. A clinical study in 25 premenopausal women with pre-diabetes took NMN supplement orally at a dose of 250 mg/day, and found that NMN increased muscle insulin sensitivity without causing any adverse events. The second clinical study focused on the effect of NMN supplementation on runners' aerobic capacity. Thirty-six participants received 300 mg/day (n=12), 600 mg/day (n=12) or 1200 mg/day (n=12) NMN, and no side effects or adverse events were reported. Although the U.S. Food and Drug Administration (FDA) has not yet approved these two ingredients for dietary supplements, NMN and NR supplements can be easily bought online, and many consumers have started taking them, with doses ranging from 500mg to 1000mg/day. No adverse events have been found.
Compared with NAM, oral NMN and NR can increase NAD+ level more efficiently and have better safety and tolerance, which is a potential treatment strategy for dermatologists to reduce the risk of keratinocyte cancer. However, it still needs a lot of clinical research data to verify its practical application in clinical treatment.
References:
[1]. Kahn B, Borrelli M, Libby T. A Narrative Review of Nicotinamide Adenine Dinucleotide (NAD)+ Intermediates Nicotinamide Riboside and Nicotinamide Mononucleotide for Keratinocyte Carcinoma Risk Reduction. J Drugs Dermatol. 2022 Oct 1;21(10):1129-1132. doi: 10.36849/JDD.6870. PMID: 36219044.
Post time: Oct-25-2022